Secrets of Lung Cancer Drug Resistance Revealed at UCSF
Discovery May Lead to New, More Powerful Precision Medicines that Thwart Resistance to the Common Lung Cancer Drug Tarceva
By Jason Bardi | July 1, 2012
People with lung cancer who are treated with the drug Tarceva face a daunting uncertainty: although their tumors may initially shrink, it's not a question of whether their cancer will return — it's a question of when. And for far too many, it happens far too soon.
Now, a team of researchers at the University of California, San Francisco's Helen Diller Family Comprehensive Cancer Center has discovered that a human protein called AXL drives resistance to Tarceva, which suggests that blocking the protein may prevent resistance to the cancer drug.
The discovery, described this week in Nature Genetics, may lead to better treatments involving precision medicines that would combine Tarceva with new drugs designed to block AXL.
"If we block AXL activation in the laboratory, we can overcome resistance to Tarceva," said Trever Bivona, MD, PhD, an assistant professor of hematology and oncology. "This paves the way for novel and more effective therapies."
In the experiments, Bivona and his colleagues used an inhibitor of AXL that is not an ideal clinical drug. But now Bivona and his team are working together with Kevan Shokat, PhD, a Howard Hughes Medical Institute Investigator and chair of the UCSF Department of Cellular and Molecular Pharmacology, to develop more potent AXL inhibitors for clinical testing.
Lung Cancer is Number One Cancer Killer
Lung cancer is the most common cause of cancer death worldwide. More people die from the disease each year than from breast, colon and prostate cancers combined. It claims more than 150,000 American lives annually and accounts for some 1.4 million deaths around the world. About 85 percent of Americans with all types of lung cancer die within five years of diagnosis.